Press Release History | Oxurion — Advancing Science. Enhancing Vision

Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

Company, THR-149 - Press Releases archive

9 Sep 2019

Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME

2 Sep 2019

Oxurion to make a late-breaker presentation of topline THR-149 (Plasma Kallikrein inhibitor) Phase 1 clinical data at EURETINA 2019

1 Jul 2019

Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME

24 Apr 2019

Oxurion NV announces full enrollment in Phase 1 trial evaluating the safety of plasma kallikrein inhibitor THR-149 for treatment of DME, ahead of schedule

28 Feb 2019

Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting

25 May 2018

ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME)

23 May 2018

ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018

6 Apr 2018

ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149

20 Apr 2017

ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema